Epsin Endocytic Adaptor Proteins in Angiogenic and Lymphangiogenic Signaling
- PMID: 37217282
- PMCID: PMC10759987
- DOI: 10.1101/cshperspect.a041165
Epsin Endocytic Adaptor Proteins in Angiogenic and Lymphangiogenic Signaling
Abstract
Circulating vascular endothelial growth factor (VEGF) ligands and receptors are central regulators of vasculogenesis, angiogenesis, and lymphangiogenesis. In response to VEGF ligand binding, VEGF receptor tyrosine kinases initiate the chain of events that transduce extracellular signals into endothelial cell responses such as survival, proliferation, and migration. These events are controlled by intricate cellular processes that include the regulation of gene expression at multiple levels, interactions of numerous proteins, and intracellular trafficking of receptor-ligand complexes. Endocytic uptake and transport of macromolecular complexes through the endosome-lysosome system helps fine-tune endothelial cell responses to VEGF signals. Clathrin-dependent endocytosis remains the best understood means of macromolecular entry into cells, although the importance of non-clathrin-dependent pathways is increasingly recognized. Many of these endocytic events rely on adaptor proteins that coordinate internalization of activated cell-surface receptors. In the endothelium of both blood and lymphatic vessels, epsins 1 and 2 are functionally redundant adaptors involved in receptor endocytosis and intracellular sorting. These proteins are capable of binding both lipids and proteins and are important for promoting curvature of the plasma membrane as well as binding ubiquitinated cargo. Here, we discuss the role of epsin proteins and other endocytic adaptors in governing VEGF signaling in angiogenesis and lymphangiogenesis and discuss their therapeutic potential as molecular targets.
Copyright © 2024 Cold Spring Harbor Laboratory Press; all rights reserved.
References
-
- Adair TH, Montani JP. 2010. Angiogenesis. Morgan & Claypool Life Sciences, San Rafael, CA. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 HL133216/HL/NHLBI NIH HHS/United States
- R01 HL146134/HL/NHLBI NIH HHS/United States
- R01 HL093242/HL/NHLBI NIH HHS/United States
- R01 HL158097/HL/NHLBI NIH HHS/United States
- R01 HL156362/HL/NHLBI NIH HHS/United States
- I01 BX004426/BX/BLRD VA/United States
- R01 HL162367/HL/NHLBI NIH HHS/United States
- R01 HL137229/HL/NHLBI NIH HHS/United States
- R01 HL118676/HL/NHLBI NIH HHS/United States
- R01 HL130845/HL/NHLBI NIH HHS/United States
- R01 HL167206/HL/NHLBI NIH HHS/United States
- R01 HL141853/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources